Pharmaceutical companies have been limiting access to lifesaving drugs through the federal 340B drug discount program since 2020, counter to the 32-year-old law that created the program. As a result, participating hospitals have seen significant drops in savings—up to 75% over three years—which they use to reduce costs and enhance services for low-income patients.